recombinant adjuvanted pandemic H5N1 vaccine (TRIA Bioscience)

N/A

Report date: 2025/03/20 09:38:18

Base Information

Drug Namerecombinant adjuvanted pandemic H5N1 vaccine (TRIA Bioscience)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Recombinant proteinVaccines > Application > Prophylactic vaccine
Mechanisms of ActionInfluenza virus hemagglutinin glycoproteins modulatorsToll like receptor 4 agonists
TargetsInfluenza virus hemagglutinin glycoproteinsToll like receptor 4
Therapy Area/IndicationsInfluenza, Human
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesTRIA Bioscience Corp
China Registration ClassN/A

Develop Information

Active CompaniesTRIA Bioscience Corp
Inactive CompaniesN/A
Active IndicationsInfluenza, Human
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A